ライフサイエンスコーパス: bulky disease

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 B, and IIA) and advanced stage (IIB-IV) with bulky disease.

2 002) for OS for patients not receiving RT to bulky disease.

3 tment, including nine objective responses in bulky disease.

4 and the presence or absence of B symptoms or bulky disease.

5 did not produce remissions in patients with bulky disease.

6 ged survival of tumor-bearing mice even with bulky disease.

7 nsitivity and for the presence or absence of bulky disease.

8 age I or II disease at diagnosis, and 13 had bulky disease.

9 794 eligible patients, 264 had stage I or II bulky disease, 135 received ABVD, and 129 received Stanf

10 nosis (including the presence of B symptoms, bulky disease, advanced stage, or extranodal disease), r

11 Patients with bulky disease and high-risk genetic features have achiev

12 ion-free survival even after controlling for bulky disease and International Prognostic Score more th

13 nted, includes irradiation of symptomatic or bulky disease and intracerebrospinal fluid chemotherapy

14 There was no limit on bulky disease, and 59% had at least one mass > or = 5 cm

15 SUVmax >/=10, PS >/=2, bulky disease, and age >/=65 were independently associat

16 c covariates included histology, presence of bulky disease, and prior treatment history.

17 Additive RT to bulky sites abrogates bulky disease as a risk factor and improves outcome of e

18 ced (stage III or IV) disease, with stage II bulky disease considered as limited or advanced disease

19 CR rate to hu14.8-IL2, whereas patients with bulky disease did not respond.

20 cs, including bone marrow involvement (41%), bulky disease > or = 5 cm (49%), and transformed histolo

21 Fourteen of 15 patients with bulky disease (> or = 5 cm) had a CR after treatment com

22 ad at least four prior regimens) and 49% had bulky disease (> or = 5 cm).

23 Responses occurred in patients with bulky disease (> or = 7 cm; 41%) and splenomegaly (50%).

24 ly, when controlling for the IPI, identified bulky disease (>/= 10 cm), thrombocytopenia (< 150 x 10(

25 range) age of 64 (32-91) years, 34 (53%) had bulky disease (>/=1 lymph nodes >/=5 cm), and 37 (58%) h

26 On univariate analysis, bulky disease (>10 cm), extranodal nonbone marrow involv

27 Four of six with bulky disease had a PR.

28 The presence of bulky disease in Hodgkin lymphoma (HL), traditionally de

29 e (P = .025) of high Ki67, high PET SUV, and bulky disease influenced overall survival (OS) and progr

30 emotherapy and consolidative radiotherapy to bulky disease is effective in bulky and advanced Hodgkin

31 elated with younger age, higher frequency of bulky disease, lower hemoglobin levels, higher leukocyte

32 This observation suggests that patients with bulky disease may require more aggressive management.

33 ment of patients with refractory or relapsed bulky disease measuring >10 cm, and retreatment of patie

34 ents required radiation (due to unresponsive bulky disease or CNS involvement).

35 a who had histologically confirmed stage IIA bulky disease or stage IIB-IV disease and an Eastern Coo

36 endamustine-rituximab as primary therapy for bulky disease, profound hematologic compromise, or const

37 Patients with platinum-resistant, bulky disease should not be transplanted.

38 port that Stanford V chemotherapy with RT to bulky disease sites is highly effective in locally exten

39 including age, sex, Ann Arbor disease stage, bulky disease status, standardized uptake values (SUVs)

40 better therapeutic results in patients with bulky disease, the application of higher, potentially my

41 , event-free survival (EFS) of patients with bulky disease was inferior without additive RT (hazard r

42 re, international prognostic score >/= 4 and bulky disease were no longer prognostic in patients who

43 , or earlier stage with systemic symptoms or bulky disease) were randomly assigned between ABVD and M

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。